Financials J2KBIO Co., Ltd.

Equities

A420570

KR7420570004

Pharmaceuticals

End-of-day quote Korea S.E. 18:00:00 2024-06-09 EDT 5-day change 1st Jan Change
31,400 KRW +5.55% Intraday chart for J2KBIO Co., Ltd. -0.63% 0.00%

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 13,858 14,219 16,032 28,472
EBITDA 1 1,461 2,380 2,695 6,241
EBIT 1 1,126 1,874 2,138 5,607
Operating Margin 8.13% 13.18% 13.33% 19.69%
Earnings before Tax (EBT) 1 1,476 1,594 2,247 5,572
Net income 1 1,475 1,623 2,121 4,844
Net margin 10.65% 11.42% 13.23% 17.01%
EPS 2 23,854 26,241 31,434 978.3
Free Cash Flow - 1,534 153.5 -752.5
FCF margin - 10.79% 0.96% -2.64%
FCF Conversion (EBITDA) - 64.44% 5.7% -
FCF Conversion (Net income) - 94.5% 7.24% -
Dividend per Share - - - 4,000
Announcement Date 22-04-11 22-04-11 23-04-06 24-03-27
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 2,443 324 - -
Net Cash position 1 - - 509 3,156
Leverage (Debt/EBITDA) 1.672 x 0.1362 x - -
Free Cash Flow - 1,534 154 -752
ROE (net income / shareholders' equity) - 20.1% 21.1% 33.4%
ROA (Net income/ Total Assets) - 7.97% 7.91% 17.7%
Assets 1 - 20,374 26,826 27,389
Book Value Per Share 2 117,233 143,350 174,115 3,533
Cash Flow per Share 2 41,980 71,705 59,898 777.0
Capex 1 1,865 799 180 1,369
Capex / Sales 13.46% 5.62% 1.12% 4.81%
Announcement Date 22-04-11 22-04-11 23-04-06 24-03-27
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. A420570 Stock
  4. Financials J2KBIO Co., Ltd.